

**\*Our Supplemental Rebate page has been updated. You can find all the information, response dates, and bid instructions there. ([www.okhca.org/supplementalrebate](http://www.okhca.org/supplementalrebate))**

**Oklahoma Health Care Authority  
Drug Utilization Review Board  
(DUR Board)  
Meeting – September 12, 2012 @ 6:00 p.m.**

Oklahoma Health Care Authority  
2401 N.W. 23<sup>rd</sup> Street, Suite 1-A  
Oklahoma City, Oklahoma 73107  
Ponca Room (North Entrance)

---

**AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
  - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
  - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
  - A. August 8, 2012 DUR Minutes – Vote
  - B. August 9, 2012 DUR Recommendation Memorandum
  - C. Correspondence

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
  - A. Retrospective Drug Utilization Review Response for March 2012
  - B. Medication Coverage Activity for August 2012
  - C. Pharmacy Help Desk Activity for August 2012
  - D. SoonerCare Atypical Rx Program Update

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

5. **Action Item – Vote to Prior Authorize Select Gonadotropin-Releasing Hormone Analogs for Central Precocious Puberty – See Appendix C.**
  - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

6. **Action Item – Atypical Antipsychotics Annual Review Follow-Up – See Appendix D.**
  - A. Background
  - B. COP Recommendations

Items to be presented by Dr. Weber, Dr. Muchmore, Chairman

7. **Action Item – Annual Review of Benign Prostatic Hyperplasia Medications and 30 Day Notice to Prior Authorize Cialis<sup>®</sup> – See Appendix E.**
  - A. Current Authorization Criteria
  - B. Utilization Review
  - C. Prior Authorization Review
  - D. Market News and Update
  - E. COP Recommendations
  - F. Utilization Details
  - G. Cialis<sup>®</sup> Product Details

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of Adcirca<sup>®</sup> and Revatio<sup>®</sup> – See Appendix F.**
  - A. Current Authorization Criteria
  - B. Utilization Review
  - C. Prior Authorization Review
  - D. Market News and Update
  - E. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Benlysta<sup>®</sup> – See Appendix G.**
  - A. Current Authorization Criteria
  - B. Utilization Review
  - C. Market News and Updates
  - D. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman

10. **30 Day notice to Prior Authorize Neupro<sup>®</sup> – See Appendix H.**
  - A. Product Summary
  - B. COP Recommendations
  - C. Product Details

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

11. **FDA and DEA Updates – See Appendix I.**
12. **Future Business**
  - A. Annual Reviews
  - B. New Product Reviews
  - C. Medical Product Reviews
13. **Adjournment**